News | Podcasts | March 16, 2025
Diabetes Dialogue: Impact of NovoCare Pharmacy, LillyDirect Self Pay on GLP-1 RA Access Author(s) Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES , Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES In this episode, hosts discuss the impact of recently launched direct, cash pay options for people using semaglutide and tirzepatide.
In the post-shortage era of GLP-1 receptor agonists (GLP-1 RAs), companies involved in the competitive landscape find themselves digging in for an extended battle—either with each other or against recent regulation...
November 16th, 2026 Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.
November 12th, 2026 TRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.
November 12th, 2026 Tom Martens, MD, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss CONNECT trial data on CGM in non-insulin-treated type 2 diabetes.
November 16th, 2026 Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss tubeless Mobi's FDA clearance, CVS Caremark's CGM formulary shift, and a transmitter-free implant.
November 17th, 2026 Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.
November 10th, 2026 Lp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.
November 9th, 2026 Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.
November 19th, 2026 Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.